Skip to Content

Amicar (aminocaproic acid) Disease Interactions

There are 3 disease interactions with Amicar (aminocaproic acid):

Major

Aminocaproic acid (applies to Amicar) myopathy

Major Potential Hazard, Low plausibility.

Skeletal muscle toxicity ranging from mild myalgia to rhabdomyolysis has been reported rarely during prolonged administration of aminocaproic acid. Therapy with aminocaproic acid should be administered cautiously in patients with or predisposed to myopathy. Clinical monitoring of muscle enzymes (particularly CPK) are recommended.

References

  1. "Product Information. Amicar (aminocaproic acid)." Immunex Corporation, Seattle, WA.
Major

Aminocaproic acid (applies to Amicar) renal dysfunction

Major Potential Hazard, High plausibility.

Aminocaproic acid is primarily eliminated by the kidney. Approximately 65% of aminocaproic acid is excreted unchanged in the urine. Serum concentrations of aminocaproic acid can be increased in patients with renal impairment. Therapy with aminocaproic acid should be administered with extreme caution in patients with upper urinary tract bleeding. Glomerular capillary thrombosis or clots in the renal pelvis and ureters have occurred in patients with upper urinary tract bleeding during aminocaproic acid therapy. Clinical monitoring of renal function, clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.

References

  1. "Product Information. Amicar (aminocaproic acid)." Immunex Corporation, Seattle, WA.
Major

Aminocaproic acid (applies to Amicar) thrombohemorrhagic disorders

Major Potential Hazard, High plausibility. Applicable conditions: Thrombotic/Thromboembolic Disorder, Disseminated Intravascular Coagulation

The use of aminocaproic acid is contraindicated in patients with active intravascular clotting. Aminocaproic acid should not be used in the presence of disseminated intravascular coagulation (DIC) without concomitant administration of heparin. Aminocaproic acid inhibits plasminogen activators and, to a lesser extent, plasmin activity, resulting in decreased fibrinolysis. Clinical monitoring of clot lysis activity and fibrinolytic determinants (profibrinolysin, fibrinolysin and anti-fibrinolysin) is recommended.

References

  1. "Product Information. Amicar (aminocaproic acid)." Immunex Corporation, Seattle, WA.

Amicar (aminocaproic acid) drug interactions

There are 12 drug interactions with Amicar (aminocaproic acid)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.